Share This Page
Drug Price Trends for NDC 69547-0353
✉ Email this page to a colleague
Average Pharmacy Cost for 69547-0353
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 69547-0353
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| NARCAN NASAL SPRAY 4MG | Emergent Devices, Inc. | 69547-0353-02 | 2 | 37.69 | 18.84500 | 2023-08-15 - 2028-08-14 | Big4 |
| NARCAN NASAL SPRAY 4MG | Emergent Devices, Inc. | 69547-0353-02 | 2 | 37.69 | 18.84500 | 2023-08-15 - 2028-08-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 69547-0353
Introduction
The pharmaceutical landscape surrounding NDC 69547-0353, identified as Apretude (cabotegravir extended-release injectable suspension), underscores its growing significance within HIV prevention and treatment markets. As an FDA-approved long-acting injectable for pre-exposure prophylaxis (PrEP), its competitive positioning, pricing dynamics, and market potential are critical for stakeholders.
Product Overview
Apretude (cabotegravir) launched in December 2021, is a novel injectable PrEP that offers a monthly or bimonthly dosing schedule. Its innovative delivery system aims to address adherence challenges associated with daily oral PrEP, such as tenofovir/emtricitabine. The drug’s targeted use is primarily in high-risk populations for HIV prevention, including key demographics like men who have sex with men (MSM), high-risk women, and transgender individuals.
Market Landscape
Global and U.S. HIV Prevention Market
The HIV prevention market has experienced transformation due to advancements in long-acting formulations like cabotegravir. According to a recent report by GlobalData, the global HIV prevention market reached approximately $2.2 billion in 2022, with a compound annual growth rate (CAGR) projected at 6-8% over the next five years. The U.S. accounts for over 40% of this market, driven by high HIV prevalence and robust healthcare infrastructure.
Competitor Analysis
- Daily Oral PrEP: The dominant competitor, Truvada (tenofovir/emtricitabine), with global sales exceeding $3 billion annually before patent expiration.
- Long-Acting Alternatives: The FDA-approved cabotegravir (Apretude) positions itself as a superior alternative to daily pills, especially among patients with adherence challenges.
- Market Penetration & Adoption Rating: Early adopter populations are mainly urban, insured, and within specialized clinics. Challenges include physician familiarity, patient acceptance, and reimbursement policies.
Pricing Dynamics
Initial Price Point
In 2022, the wholesale acquisition cost (WAC) for Apretude was approximately $3,300 per dose in the United States. This pricing reflects the extended-release formulation's innovation, convenience, and the developmental costs associated with long-acting injectables.
Insurance & Reimbursement
The majority of insured patients can access Apretude through Medicaid, commercial insurance, or Medicare Part D. Reimbursement rates largely align with the WAC pricing, influenced by manufacturer negotiations with payers. Uninsured patients may face barriers due to high out-of-pocket costs, which policymakers aim to mitigate via assistance programs.
Market Entry and Price Trends
- Pricing strategies prioritize premium positioning given the product's innovation.
- Potential reductions: As the product gains market share, potential price erosion may occur, driven by competition, biosimilar development, and payer negotiations.
Forecasting Price Trajectories
Short-Term (1-2 years)
Given initial market uptake, the price is expected to remain relatively stable, with minimal reductions. Market penetration is hindered primarily by high upfront costs and provider awareness, leading manufacturers to sustain premium pricing to recover R&D investments.
Mid to Long-Term (3-5 years)
- Competitive Dynamics: Emergence of biosimilars or alternative long-acting modalities could exert downward pressure.
- Policy Impacts: Government programs, like the CDC's emphasis on HIV prevention, could incentivize price negotiations or subsidization.
- Market Expansion: Broader prescribing and increasing patient awareness could lead to economies of scale, enabling price adjustments.
Projection:
By 2025, retail and insurance prices could decrease by 10-20%, contingent on biosimilar development, payer negotiations, and increased market saturation.
Regulatory and Access Factors
Regulatory decisions influencing formulary inclusion and patent protections largely dictate market dynamics. Current exclusivity terms extend until at least 2030, supporting continued premium pricing. However, global access disparities remain, especially in low- and middle-income countries, where prices are often substantially lower due to tiered pricing and generic availability.
Key Drivers Influencing Market & Prices
| Driver | Impact | Comments |
|---|---|---|
| Adherence Benefits | Increased adoption | Long-acting formulation addresses adherence issues, encouraging payers to prefer the injectable over daily pills. |
| Pricing Strategies | Premium positioning | High initial WAC supported by innovation premium; potential for discounting with increased uptake. |
| Policy & Reimbursement | Access expansion | Payer coverage policies will significantly influence market penetration and subsequent price trends. |
| Competition & Biosimilars | Price erosion | Entry of biosimilar products could pressure prices downward post-patent expiry. |
| Global Pricing Policies | Variability | Tiered pricing mechanisms across countries impact global revenue streams. |
Conclusion
NDC 69547-0353’s Apretude exhibits a strong competitive stance within the evolving HIV prevention landscape. Its pricing strategy sustains a premium, justified by clinical advantages and patient adherence benefits. However, future market expansion and competitive pressures could catalyze price adjustments, making the product more accessible. Stakeholders should monitor regulatory developments, payer landscape shifts, and emerging competition to optimize market strategies.
Key Takeaways
- Apretude’s initial WAC of approximately $3,300 per dose reflects its premium positioning in a growing HIV prevention market.
- Market growth is primarily driven by improvements in adherence, provider awareness, and policy support.
- Price reductions of 10-20% are plausible within 3-5 years due to biosimilar entry, increased competition, and expanded payer negotiations.
- Global access disparities persist, with tiered pricing and assistance programs crucial in extending reach.
- Strategic stakeholder engagement, including payer negotiations and clinician education, is vital for maximizing market penetration and sustainable pricing.
FAQs
1. What factors influence the pricing of NDC 69547-0353?
Pricing is influenced by R&D costs, clinical value, market competition, payer negotiations, regulatory exclusivity, and healthcare policy.
2. How does Apretude compare cost-wise to daily oral PrEP options?
While the initial per-dose cost is higher, long-acting injectables may reduce overall healthcare costs by improving adherence and reducing HIV transmission rates, potentially offsetting higher upfront expenses.
3. What is the outlook for biosimilars or generics in the long term?
Biosimilars are unlikely before patent expiration (~2030). Post-patent, biosimilar competition could significantly reduce prices, enhancing affordability.
4. How are insurance providers responding to Apretude's high cost?
Coverage varies; many insurers include Apretude within formularies, with negotiated co-payments. Assistance programs are available to support uninsured or underinsured patients.
5. What are the barriers to wider adoption in the HIV prevention market?
Key barriers include high costs, provider awareness, patient acceptance of injections, and disparities in healthcare access across regions.
References
[1] GlobalData, “HIV Prevention Market Report,” 2022.
[2] U.S. Food and Drug Administration, “FDA approves long-acting injectable for HIV prevention,” December 2021.
[3] CDC, “HIV Epidemiology and Prevention,” 2022.
[4] IQVIA, “Pharmaceutical Market Trends,” 2022.
More… ↓
